ArticleInvestigational new drugs2012

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia.

Simona Lapusan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.